First for Women on MSN20h
Amycretin Shows Promising 22% Weight Loss in Trials-It May Rival Ozempic
Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...
pharmaphorum17h
Novo Nordisk, Lilly highlight oral obesity drugs at ADA
New data from Novo Nordisk’s phase 3 trial of ... but extending its use into non-diabetic obesity could unlock an even larger market for the drug. A once-weekly injectable form of the drug ...
pharmaphorum17h
Novo Nordisk steps up sickle cell push with $1.1bn Forma buy
Novo Nordisk licensed rights to EPI01 from EpiDestiny in 2018, paying $400 million for rights to the drug in haemaglobinopathies ... focus of diabetes and obesity, which has also seen it move ...
Wall Street Journal17h
Novo Nordisk A/S ADR
$ 81.33 0.23 0.28% ...